Programme
08:30
Registration
09:00
Opening/Welcome
René Leemans/Andreas Dietz/Wojciech Golusinski
Epidemiology and carcinogenesis
Chairs: Andreas Dietz/Wojciech Golusinski
09:20
Epidemiology of oral/oropharyngeal HPV infection
Maura Gillison
09:40
HPV-mediated carcinogenesis
Ruud Brakenhoff
10:00
Worldwide incidence of HPV in OPSCC
Pawel Golusinski
10:20
Coffee
10:15
Mucosal stem cells and HPV infection
Jochen Hess
11:10
Free papers 4x
Prognosis and serology HPV in OPSCC
Chairs: Ruud Brakenhoff/ Maura Gillison
11:50
Validation of statistical models for OPSCC
Robert Baatenburg de Jong
12:10
Subclassification of HPV-OPSCC by gene expression
Lisa Licitra
12:30
HPV early antigen serology and OPC screening
Tim Waterboer
12:45
Antibody producing B-cells in HPV+ve OPSCC: an overview
Rieneke van de Ven
13:00
Lunch
Treatment of HPV+ve OPSCC
Chairs: René Leemans/Bob Ferris
14:00
Treatment of HPV disease by transoral robotic surgery
Christian Simon
14:20
Treatment of HPV disease by laser surgery
Terry Jones
14:40
Treatment of HPV disease with (chemo)radiotherapy
Vincent Gregoire
15:00
Free papers 3x
15:30
Coffee
T.B.C.
Chairs: Christian Simon/Stephan Lang
16:00
Are there alternatives for 3 weekly cisplatin in HPV disease?
Jan Vermorken
16:20
Salvage surgery for HPV disease
Carole Fakhry
Debate
16:40
Debate: This house believes that TNM8 was implemented too early for HPV+ve OPSCC
For: Hisham Mehanna / Against: Brian O’Sullivan
17:00
Posters and Drinks
Therapy developments in HPV+ve OPSCC
Chairs: Jan Vermorken/Vincent Gregoire
09:00
Free papers 3x
09:30
De-escalation of non-surgical therapy
Hisham Mehanna
09:50
De-escalation using surgery
Bob Ferris
10:10
Is proton therapy preferable for HPV+ve OPSCC?
Hans Langendijk
10:30
Coffee
T.B.C.
Chairs: Lisa Licitra/Hans Langendijk
11:00
Free papers 2x
11:20
Next generation robotics
Stephan Lang
11:40
Immunotherapy for HPV-driven disease
Maura Gillison
12:00
Tumor board (moderator: Terry Jones)
Wojciech Golusinski, Stephan Lang, Hans Langendijk, Lisa Licitra, Bob Ferris
13:00
Lunch
Future perspectives in HPV research
Chairs: Rieneke van de Ven/Ingeborg Tinhofer-Keilholz
14:00
Therapeutic HPV vaccination
Sjoerd van der Burg
14:20
HPV in non-oropharygeal HNSCC: does it play a role?
Gunnar Wichmann
14:40
Free papers 3x
Screening and Prevention
Chair: Andreas Dietz
15:10
Round table screening and prevention
Discussion leader: Andreas Dietz
5-slide Pitch Hans Berkhof: Preventive vaccination, also in treated OPSCC patients?
5-slide Pitch Tim Waterboer: HPV serology for screening
5-slide Pitch Ingeborg Tinhofer-Keilholz: HPV DNA assays for screening
5-slide Pitch Carole Fakhry: Positively screened for HPV: which intervention?
16:00
Round table discussion: screening and prevention
16:30
Summary
Wojciech Golusinski
16:40
Free paper/Poster awards and closing remarks
René Leemans
16:50
Adjourn